1. Home
  2. LABT vs EZRA Comparison

LABT vs EZRA Comparison

Compare LABT & EZRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lakewood-Amedex Biotherapeutics Inc. Common Stock

LABT

Lakewood-Amedex Biotherapeutics Inc. Common Stock

N/A

Current Price

$0.84

Market Cap

2.2M

Sector

Health Care

ML Signal

N/A

Logo Reliance Global Group Inc. Common Stock

EZRA

Reliance Global Group Inc. Common Stock

N/A

Current Price

$2.51

Market Cap

1.9M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
LABT
EZRA
Founded
2006
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Specialty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.2M
1.9M
IPO Year
2026
2020

Fundamental Metrics

Financial Performance
Metric
LABT
EZRA
Price
$0.84
$2.51
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 638.8K
55.9K
Earning Date
11-18-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 85.79
EPS
★ N/A
N/A
Revenue
N/A
★ $12,430,959.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.82
$0.11
52 Week High
$6.85
$5.45

Technical Indicators

Market Signals
Indicator
LABT
EZRA
Relative Strength Index (RSI) 26.61 45.70
Support Level N/A $2.10
Resistance Level $2.13 $3.12
Average True Range (ATR) 0.21 0.24
MACD -0.10 -0.04
Stochastic Oscillator 1.78 55.56

Price Performance

Historical Comparison
LABT
EZRA

About LABT Lakewood-Amedex Biotherapeutics Inc. Common Stock

Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.

About EZRA Reliance Global Group Inc. Common Stock

Reliance Global Group Inc operates as a holding company that acquires, owns, and actively manages insurance and technology-focused businesses. The company focuses on growing by pursuing acquisition strategies initially, and focuses on wholesale and retail insurance agencies. Its primary move is to identify specific risks to reward arbitrage opportunities and develop these on a national platform, thereby increasing revenues and returns, and then identify and acquire undervalued wholesale and retail insurance agencies with operations in growing or underserved segments, expand and optimize their operations. The Company operates as a single operating segment, the Insurance Segment, earning its revenues from insurance commissions.

Share on Social Networks: